Pulmonary Hypertension

The Evolving Treatment Landscape of Pulmonary Arterial Hypertension - AJMC.com Managed Markets Network The Evolving Treatment Landscape of Pulmonary Arterial Hypertension - AJMC.com Managed Markets Network Posted: 11 Mar 2021 12:00 AM PST Am J Manag Care . 2021;27(3):S42-S52. https://doi.org/10.37765/ajmc.2021.88610 Goals of Therapy in Pulmonary Arterial Hypertension The goals of therapy in pulmonary arterial hypertension (PAH) include alleviation of symptoms, improved exercise capacity, improvement in quality of life (QOL), preservation of right ventricular (RV) function, and reduction of mortality risk. 1,2 The European Society of Cardiology and the European Respiratory Society (ESC/ERS) 2015 guidelines propose several factors that aid in determining whether a person with PAH has a low, intermediate, or high risk of 1-year mortality. These factors include presence of right heart failure, progression of symptoms, syncope, World Health Or...

What to Expect During Pulmonary Embolism Recovery - Healthline What to Expect During Pulmonary Embolism Recovery - Healthline Posted: 19 May 2021 08:13 AM PDT A pulmonary embolism (PE) is when a blood clot becomes stuck in the blood vessels of your lung. These clots typically begin in the leg and then break free and travel to the lung. The American Lung Association estimates that about 1 in 1,000 people in the United States experience a PE each year. A PE can be a serious or life threatening condition, which means receiving prompt medical treatment is vital. Treatment of a PE focuses on making sure that the current clot doesn't get any bigger while also preventing new clots from forming. Recovery from a PE can take several weeks or months. Continue reading to learn more about: how long it can take to recover from a PE the treatments you may receive when you can go back to your normal activities The exact amount of ...

Bosentan to Ambrisentan in Pulmonary Arterial Hypertension | IJGM - Dove Medical Press Bosentan to Ambrisentan in Pulmonary Arterial Hypertension | IJGM - Dove Medical Press Posted: 25 May 2021 02:45 PM PDT Introduction Pulmonary arterial hypertension (PAH) is a chronic and devastating disease characterized by progressively increasing pulmonary artery pressure and vascular resistance that results in right heart failure and death. Despite multiple treatment options, the prognosis of pulmonary arterial hypertension (PAH) remains poor. 1–3 Transition to pulmonary arterial hypertension (PAH)-specific drugs is considered in patients with PAH who do not respond to a therapeutic pathway or who experience side effects to the combination of drugs. Several studies have compared the transition of medicines from one pathway to another. However, little is known about the transition between the same category, especially in the endothelin receptor anta...